The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The use of oral ixazomib maintenance following autoSCT in patients with NDMM
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses a study on oral ixazomib maintenance after autologous stem cell transplantation (autoSCT) in newly diagnosed multiple myeloma (NDMM). The study showed improved progression-free survival (PFS) compared to placebo, but Dr Dimopoulos notes that lenalidomide remains the preferred maintenance therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen, Sanofi, Regeneron, Celgene, Menarini, Takeda, GSK, BMS, Janssen, Beigene, Swixx, Astra Zeneca.
